American Association for Cancer Research
21598290cd201213-sup-249662_2_supp_6995730_qq6s38.pdf (34.31 kB)

Supplementary Table S1 from Selective Modulation of a Pan-Essential Protein as a Therapeutic Strategy in Cancer

Download (34.31 kB)
journal contribution
posted on 2023-04-03, 23:24 authored by Clare F. Malone, Neekesh V. Dharia, Guillaume Kugener, Alexandra B. Forman, Michael V. Rothberg, Mai Abdusamad, Alfredo Gonzalez, Miljan Kuljanin, Amanda L. Robichaud, Amy Saur Conway, Joshua M. Dempster, Brenton R. Paolella, Nancy Dumont, Volker Hovestadt, Joseph D. Mancias, Scott T. Younger, David E. Root, Todd R. Golub, Francisca Vazquez, Kimberly Stegmaier

CRISPR guide sequences





Cancer dependency maps, which use CRISPR/Cas9 depletion screens to profile the landscape of genetic dependencies in hundreds of cancer cell lines, have identified context-specific dependencies that could be therapeutically exploited. An ideal therapy is both lethal and precise, but these depletion screens cannot readily distinguish between gene effects that are cytostatic or cytotoxic. Here, we use a diverse panel of functional genomic screening assays to identify NXT1 as a selective and rapidly lethal in vivo relevant genetic dependency in MYCN-amplified neuroblastoma. NXT1 heterodimerizes with NXF1, and together they form the principal mRNA nuclear export machinery. We describe a previously unrecognized mechanism of synthetic lethality between NXT1 and its paralog NXT2: their common essential binding partner NXF1 is lost only in the absence of both. We propose a potential therapeutic strategy for tumor-selective elimination of a protein that, if targeted directly, is expected to cause widespread toxicity. We provide a framework for identifying new therapeutic targets from functional genomic screens. We nominate NXT1 as a selective lethal target in neuroblastoma and propose a therapeutic approach where the essential protein NXF1 can be selectively eliminated in tumor cells by exploiting the NXT1–NXT2 paralog relationship.See related commentary by Wang and Abdel-Wahab, p. 2129.This article is highlighted in the In This Issue feature, p. 2113

Usage metrics

    Cancer Discovery



    Ref. manager